Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 12

Specific IgA against Pseudomonas aeruginosa in severe COPD

Authors Millares L, Martí S, Ardanuy C, Liñares J, Santos S, Dorca J, García-Nuñez M, Quero S, Monsó E

Received 12 May 2017

Accepted for publication 25 July 2017

Published 30 September 2017 Volume 2017:12 Pages 2807—2811


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Richard Russell

Laura Millares,1–3 Sara Martí,2,4 Carmen Ardanuy,2,4 Josefina Liñares,2,4 Salud Santos,2,5 Jordi Dorca,5 Marian García-Nuñez,1–3,6 Sara Quero,3,6 Eduard Monsó2,7,8

1Department of Respiratory Medicine, Fundació Parc Taulí, Sabadell, Spain; 2CIBER de Enfermedades Respiratorias, CIBERES, Bunyola, Spain; 3Universitat Autònoma de Barcelona, Esfera UAB, Barcelona, Spain; 4Department of Microbiology, Hospital Universitari de Bellvitge-Universitat de Barcelona-IDIBELL, L’Hospitalet de Llobregat, Spain; 5Department of Respiratory Medicine, Hospital Universitari de Bellvitge-Universitat de Barcelona-IDIBELL, L’Hospitalet de Llobregat, Spain; 6Infectious Diseases Unit, Fundació Insitut d’Investigació GermansTrias i Pujol, Badalona, Spain; 7Department of Respiratory Medicine, Hospital Universitari Parc Taulí, Sabadell, Spain; 8Department of Medicine, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain

Background: The bronchial mucosa is protected by a specialized immune system focused on the prevention of colonization and infection by potentially pathogenic microorganisms (PPMs). Immunoglobulin A (IgA) is the principal antibody involved in this mechanism. A defective immune barrier may facilitate the recurrent presence of PPMs in COPD.
Purpose: The aim of this study was to determine IgA-mediated bronchial specific immune responses against Pseudomonas aeruginosa in stable patients with severe disease.
Methods: COPD patients with good-quality sputum samples obtained during stability were included and classified according to the presence or absence of chronic bronchial colonization by P. aeruginosa. Levels of specific IgA for P. aeruginosa in sputum were determined by ELISA and expressed as ratios, using the pooled level of 10 healthy subjects as reference (optical density450 patient/control).
Results: Thirty-six stable COPD patients were included, 15 of whom had chronic colonization by P. aeruginosa. Levels of specific IgA against P. aeruginosa in stable non-colonized patients were lower than those in healthy subjects (IgA ratio: median =0.15 [interquartile range {IQR} 0.05–0.36]). Colonized patients had higher levels, (1.56 [IQR 0.59–2.79]) (p<0.001, Mann–Whitney U test), with figures equivalent but not exceeding the reference value.
Conclusion: IgA-based immune response against P. aeruginosa was low in severe COPD patients. Levels of specific IgA against this microorganism were higher in colonized patients, but did not attain clear-cut levels above the reference. An impaired local response against P. aeruginosa may favor chronic colonization and recurrent infections in severe COPD.

Keywords: immunoglobulin A, sputum, COPD, colonization, ELISA

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]